Long-term study of Angelman syndrome
Part of Brain & nervous system, Genetic & congenital clinical trials.
This study follows people with Angelman syndrome over time to learn more about the condition. It does not test any new treatments, but you need a parent or caregiver to come with you to all visits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of Angelman syndrome (with a known genetic change in the UBE3A gene).
- You are at least 1 year old.
- You have a parent or caregiver (study partner) who is at least 18, speaks English, and can come with you to all visits.
- You have not changed any medications or therapies in the last 4 weeks.
- You have not had a seizure-related hospital visit in the last 4 weeks.
- You have not received any gene- or cell-based treatments in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with Angelman syndrome to understand how their symptoms and development change over time. It may help researchers better describe the condition and support future treatments.
This study follows people with Angelman syndrome over time to learn more about the condition. You can join if you have a confirmed genetic diagnosis and your caregiver agrees to take part.
This study tests an experimental medicine for Angelman syndrome (AS), a genetic condition affecting the nervous system. The medicine is given by lumbar puncture and aims to improve symptoms.
This trial uses eye tracking to understand how children with Angelman syndrome perceive social cues. Participation helps researchers learn more about social perception for future treatments.
This study tests an experimental medicine called MVX-220 to see if it is safe and effective for people with Angelman Syndrome. It includes both children (ages 4-8) and adults (ages 18-50) who can walk independently and have stable seizure medications.
This trial is building a global registry for people diagnosed with Angelman syndrome. It helps researchers learn more about how symptoms change over time, which can support future studies and treatments.
Hear when a new Angelman Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.